Relying on the DNA-PK activation-dependent intrinsic immune response to IFN regulatory factor 3 (IRF-3) [94,95], the combined DNA-PK inhibitors blocked DNA-PK pathway and decreased IRF-3 to promote the proliferation and expansion of OV M1 in tumor cells. The gene discussed is PRKDC; the disease is neoplasm.